Three-Drug Regimen Treats Cystic Fibrosis in Younger Children

The safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) for the treatment of cystic fibrosis with at least one F508del-CFTR allele in children aged 6 to 11 years are consistent with the results reported for this combination in adolescents and adults, according to a study published online March 18 in the American Journal of Respiratory and Critical Care Medicine.